| |
Monday, October 17, 2022 | 11am ET / 8am PT Given the wide array of post transcriptional and post translational regulatory processes that govern cellular dynamics, additional omics types are needed to capture a more comprehensive understanding of the molecular landscape of a tumor. Register now to learn more.
|
|
Today's Big NewsOct 10, 2022 |
| By Max Bayer Merck's sotatercept passed a critical phase 3 test for patients with pulmonary arterial hypertension, improving their distance in the six-minute walk test. The results have teed the company up to head to regulators and emphasize the lofty ambitions Merck has for the drug. |
|
|
|
By Nick Paul Taylor ImmunityBio’s push to hire 300 people at its New York facility in 30 months has made a bad start. Rather than add to its headcount, Patrick Soon-Shiong’s biotech has outlined plans to lay off 38 people by the end of the year. |
By Max Bayer The CEO of the Biotech Innovation Organization (BIO), one of the top lobbying groups for the biopharma industry, is on leave amid internal dissent over her leadership, the Wall Street Journal reported. |
By Nick Paul Taylor Andera Partners has raised its biggest life sciences fund yet. After smashing its previous record in 2017, the European VC shop has gone one better again this time around, reeling in 456 million pounds ($443 million) to make a fresh round of biotech bets. |
By Conor Hale In light of the country’s expected growth as a medtech market, Siemens Healthineers has made the decision to split China out from the Asia-Pacific region at the corporate level, elevating it to its own seat at the company’s table. |
By Helen Floersh STING agonists have shown promise in preclinical research as mono- and adjunctive therapies, but they’ve faltered when it’s time to translate them to the clinic. Now, researchers have elucidated a mechanism that could explain why, as well as shown that a dual therapy might improve the drugs’ efficacy. |
By Kevin Dunleavy Slowly but surely over the last two decades, GSK has worked to give more people access to its tetanus, diptheria and whooping cough vaccine Boostrix. Now, expecting mothers can pass a measure of protection to their soon-to-be-born babies. On Friday, the FDA expanded use of Boostrix (Dtap) to mothers in their third trimester of pregnancy to safeguard against pertussis (whooping cough), in infants younger than two months old. |
By Annie Burky CommonSpirit Health is managing an IT security incident affecting some of its facilities in multiple regions including Nebraska, Tennessee and Washington state. The number of facilities affected is still undisclosed as is the security of patient data following the incident which reportedly began Monday. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we talk about trial results for Eisai and Biogen's Alzheimer’s drug, which were surprisingly good, and we dig into what comes next. We also discuss how Pfizer is ramping up its DTC ad campaign for its COVID shots, most recently spending big on a booster ad for the NFL season. |
|
|---|
|
|
|
Scaling biotechs are at a unique intersection of capital, opportunity and flexibility. And real estate is key to driving business forward. Get answers to six key questions to ensure you have the space and solutions to grow where and when you need to. Learn more.
|
|
| eBookIn this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
| eBookWith real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
| Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT Data |
| WhitepaperSaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
| WhitepaperRead about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
| WhitepaperThis paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
| Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services |
| VideoLearn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
| VideoCan an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WebinarYpsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
| Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
| eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
| Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
| Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
